KC1101 / Konruns Pharma - LARVOL DELTA

TACC3 inhibition with KC1101 drives mitotic catastrophe and broad antitumor activity (AACR 2026) - "A wide safety margin in exploratory toxicology, coupled with low interspecies PK variability in mouse, rat, and dog, supports future clinical investigation.In conclusion, KC1101 delivers best-in-class potential for TACC3-addicted tumors by coupling strong mitotic-catastrophe biology with consistent, QD oral efficacy—including intracranial and hematologic settings—while avoiding primary-cell cytotoxicity. Collectively with the clinical precedent for TACC3 inhibition (AO-252), these data nominate KC1101 for IND in 2026."

Oncology • Triple Negative Breast Cancer • TACC3